000120527 001__ 120527
000120527 005__ 20240228145450.0
000120527 0247_ $$2doi$$a10.1186/s13046-017-0496-2
000120527 0247_ $$2pmid$$apmid:28166815
000120527 0247_ $$2pmc$$apmc:PMC5294868
000120527 0247_ $$2ISSN$$a0392-9078
000120527 0247_ $$2ISSN$$a1756-9966
000120527 0247_ $$2altmetric$$aaltmetric:81012887
000120527 037__ $$aDKFZ-2017-00956
000120527 041__ $$aeng
000120527 082__ $$a610
000120527 1001_ $$0P:(DE-HGF)0$$aGrünow, Jennifer$$b0$$eFirst author
000120527 245__ $$aRegulation of submaxillary gland androgen-regulated protein 3A via estrogen receptor 2 in radioresistant head and neck squamous cell carcinoma cells.
000120527 260__ $$aBerlin$$bSpringer$$c2017
000120527 3367_ $$2DRIVER$$aarticle
000120527 3367_ $$2DataCite$$aOutput Types/Journal article
000120527 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1510656896_6385
000120527 3367_ $$2BibTeX$$aARTICLE
000120527 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120527 3367_ $$00$$2EndNote$$aJournal Article
000120527 520__ $$aMolecular mechanisms of intrinsic or acquired radioresistance serve as critical barrier for curative therapy of head and neck squamous cell carcinoma (HNSCC) and remain a major obstacle for progression-free and disease-specific survival.HNSCC cell lines were treated with a protocol of fractionated irradiation (IR, 4× 2Gy) alone or in combination with antagonists of estrogen receptor signaling and viability was determined by a colony-forming assay (CFA). Expression of submaxillary gland androgen-regulated protein 3A (SMR3A) and estrogen receptor 2 (ESR2) were assessed in tumor cells in vitro by RQ-PCR, Western blot analysis and immunofluorescence staining, and by immunohistochemical staining of tissue microarrays containing tumor sections from patients with oropharyngeal squamous cell carcinoma (OPSCC), which were treated by definitive or adjuvant radiotherapy. Subgroups with distinct SMR3A and ESR2 expression patterns were correlated with clinical parameters and survival outcome including multivariable analysis.Fractionated irradiation (IR) revealed an accumulation of tumor cells with prominent SMR3A expression, which was accompanied by an up-regulation of the estrogen receptor 2 (ESR2). ESR2-dependent regulation of SMR3A was supported by induced expression after stimulation with estradiol (E2), which was impaired by co-treatment with 4-Hydroxytamoxifen (TAM) or Fulvestrant, respectively. Both drugs significantly sensitized FaDu cells to fractionated IR as determined by a CFA and accelerated apoptosis. These data suggest a critical role of ESR2 in radioresistance and that SMR3A might serve as a surrogate marker for active ESR2 signaling. In line with this assumption, ESR2-positive oropharyngeal squamous cell carcinoma (OPSCC) with high SMR3A expression had an unfavorable progression-free and disease-specific survival as compared to those tumors with low SMR3A expression.In summary, our findings provide compelling experimental evidence that HNSCC with SMR3A and ESR2 co-expression have a higher risk for treatment failure and these patients might benefit from clinically well-established drugs targeting estrogen receptor signaling.
000120527 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000120527 588__ $$aDataset connected to CrossRef, PubMed,
000120527 7001_ $$aRong, Chao$$b1
000120527 7001_ $$aHischmann, Jan$$b2
000120527 7001_ $$aZaoui, Karim$$b3
000120527 7001_ $$aFlechtenmacher, Christa$$b4
000120527 7001_ $$aWeber, Klaus-Josef$$b5
000120527 7001_ $$aPlinkert, Peter$$b6
000120527 7001_ $$00000-0003-3493-1711$$aHess, Jochen$$b7$$eLast author
000120527 773__ $$0PERI:(DE-600)2430698-8$$a10.1186/s13046-017-0496-2$$gVol. 36, no. 1, p. 25$$n1$$p25$$tJournal of experimental & clinical cancer research$$v36$$x1756-9966$$y2017
000120527 909CO $$ooai:inrepo02.dkfz.de:120527$$pVDB
000120527 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000120527 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-3493-1711$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000120527 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000120527 9141_ $$y2017
000120527 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ EXP CLIN CANC RES : 2015
000120527 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120527 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120527 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120527 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000120527 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000120527 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000120527 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000120527 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000120527 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120527 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120527 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120527 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000120527 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000120527 9201_ $$0I:(DE-He78)G405-20160331$$kG405$$lMolekulare Grundlagen von HNO-Tumoren$$x0
000120527 980__ $$ajournal
000120527 980__ $$aVDB
000120527 980__ $$aI:(DE-He78)G405-20160331
000120527 980__ $$aUNRESTRICTED